Angiodynamics Return on Equity (ROE) Growth & History (ANGO)

Angiodynamics's return on equity was −20.77% for fiscal 2026.

View full Angiodynamics company overview

Angiodynamics annual return on equity history

Angiodynamics annual return on equity

Fiscal yearPeriod endedReturn on equityChange (percentage points)
20262026-05-31−20.77%−3.27 pp
20252025-05-31−17.50%+45.65 pp
20242024-05-31−63.15%−50.08 pp
20232023-05-31−13.07%−6.92 pp
20222022-05-31−6.15%+0.91 pp
20212021-05-31−7.06%+24.13 pp
20202020-05-31−31.18%−41.78 pp
20192019-05-3110.60%+7.51 pp
20182018-05-313.09%+2.11 pp
20172017-05-310.98%+9.26 pp
20162016-05-31−8.28%−7.66 pp
20152015-05-31−0.63%−1.07 pp
20142014-05-310.44%+0.64 pp
20132013-05-31−0.20%+0.95 pp
20122012-05-31−1.15%−3.17 pp
20112011-05-312.03%

Angiodynamics return on equity trends

Over the last five fiscal years, Angiodynamics's return on equity decreased from −7.06% to −20.77%, a change of −13.72 percentage points. The latest reported quarter, Q4 2026, shows −6.63%.

About the metric

What return on equity (ROE) means

Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.

Calculation and source

How return on equity is calculated

TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Angiodynamics source filings ↗

Community posts

It’s quiet here.

No posts about ANGO yet. Start the conversation.

Write the first post